CA2453572A1 - The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction - Google Patents

The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction Download PDF

Info

Publication number
CA2453572A1
CA2453572A1 CA002453572A CA2453572A CA2453572A1 CA 2453572 A1 CA2453572 A1 CA 2453572A1 CA 002453572 A CA002453572 A CA 002453572A CA 2453572 A CA2453572 A CA 2453572A CA 2453572 A1 CA2453572 A1 CA 2453572A1
Authority
CA
Canada
Prior art keywords
compounds
enhance
effects
apomorphine
phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002453572A
Other languages
English (en)
French (fr)
Inventor
Jose Esteve-Soler
Inigo Saenz De Tejada-Gorman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2453572A1 publication Critical patent/CA2453572A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002453572A 2001-07-02 2002-07-01 The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction Abandoned CA2453572A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200101535A ES2180446B1 (es) 2001-07-02 2001-07-02 Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
ESP0101535 2001-07-02
PCT/ES2002/000325 WO2003004097A1 (es) 2001-07-02 2002-07-01 Empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos en la elaboración de un medicamento para potenciar el efecto de otros fármacos en el tratamiento de la disfunción eréctil

Publications (1)

Publication Number Publication Date
CA2453572A1 true CA2453572A1 (en) 2003-01-16

Family

ID=8498259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002453572A Abandoned CA2453572A1 (en) 2001-07-02 2002-07-01 The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction

Country Status (14)

Country Link
US (2) US20040143010A1 (https=)
EP (1) EP1413332B1 (https=)
JP (1) JP2005501031A (https=)
AR (1) AR036124A1 (https=)
AT (1) ATE419012T1 (https=)
BR (1) BR0211315A (https=)
CA (1) CA2453572A1 (https=)
DE (1) DE60230629D1 (https=)
ES (2) ES2180446B1 (https=)
HU (1) HUP0400924A3 (https=)
MX (1) MXPA04000007A (https=)
NO (1) NO20040007L (https=)
PL (1) PL367766A1 (https=)
WO (1) WO2003004097A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208123A1 (es) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
RU2281101C2 (ru) * 2004-10-01 2006-08-10 Юрий Михайлович Есилевский Способ лечения больных хроническим простатитом
EP1676573A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
ES2731298T3 (es) 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
CA2771389C (en) 2009-08-21 2019-04-09 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
CN109678764A (zh) * 2018-12-05 2019-04-26 湖北广辰药业有限公司 一种羟苯双磺酸及其钙盐和制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681503A (en) * 1970-04-17 1972-08-01 Om Lab Sa Method for combating disturbances of the lipid content of the blood
US4252821A (en) * 1979-12-07 1981-02-24 Laboratoires Om Societe Anonyme Method for treating ulcers
US4511557A (en) * 1981-08-24 1985-04-16 Gauri Kailash Kumar Pharmaceutical composition
US4513007A (en) * 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
RU1776408C (ru) * 1990-08-13 1992-11-23 Одесский Медицинский Институт Им.Н.И.Пирогова Способ лечени гломерулонефрита
JP2000508308A (ja) * 1996-04-03 2000-07-04 ラボラトリオス デル ドクトール エステベ，エス．アー． 内皮機能の正常化、性的機能障害、糖尿病の血管合併症及び内皮起源の血管障害の治療用の医薬の製造のための２，５―ジヒドロキシベンゼンスルホン酸誘導体の使用
HU225149B1 (en) * 1996-12-30 2006-07-28 Teva Gyogyszergyar Zrt Use of dobesilate salts for the manufacture of medicaments for the treatment or prevention of embryonic retardation or discordance
US6403643B1 (en) * 1997-04-03 2002-06-11 Laboratories Del Dr. Esteve, S.A. Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition

Also Published As

Publication number Publication date
US20070197543A1 (en) 2007-08-23
HUP0400924A2 (hu) 2004-07-28
WO2003004097A1 (es) 2003-01-16
NO20040007L (no) 2004-02-23
EP1413332A1 (en) 2004-04-28
ES2318023T3 (es) 2009-05-01
JP2005501031A (ja) 2005-01-13
ES2180446B1 (es) 2004-01-16
BR0211315A (pt) 2004-09-28
EP1413332B1 (en) 2008-12-31
DE60230629D1 (de) 2009-02-12
MXPA04000007A (es) 2004-05-21
US20040143010A1 (en) 2004-07-22
ATE419012T1 (de) 2009-01-15
PL367766A1 (en) 2005-03-07
HUP0400924A3 (en) 2007-11-28
ES2180446A1 (es) 2003-02-01
AR036124A1 (es) 2004-08-11

Similar Documents

Publication Publication Date Title
EP1413332B1 (en) Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction
AR036448A1 (es) Composiciones farmaceuticas de conjugados droga insulina-oligomeros, y metodos para tratar las enfermedades con los mismos
JP6163633B2 (ja) 疼痛、そう痒および炎症を処置するために局所的に投与されるストロンチウム含有複合体
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
WO2003001982A3 (en) Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
ATE309802T1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
US20150080403A1 (en) Methods and compositions for treating parkinson's disease
EA200400888A1 (ru) Фармацевтически приемлемые тельца, несущие фосфат глицерина
JP2017501133A (ja) Ｃｘｃｒ拮抗性ペプチド及びその用途
TNSN04235A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
DE60022478D1 (de) Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen
WO2004043365A3 (en) Method for treatment of premature ejaculation in humans
MX2022009081A (es) Absorcion celular.
WO2006071564A3 (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
Mozhayeva et al. The effect of frusemide on oxytocin‐induced contractions of the rat myometrium
RU2568588C2 (ru) Применение воды с отрицательным окислительно-восстановительным потенциалом меньше нуля в качестве основы гелей для билогически активных добавок в виде геля.
SU886907A1 (ru) Способ лечени ожогов
RU2004105765A (ru) Способ лечения дистрофических заболеваний заднего полюса глаза
Marin et al. Peloidotherapy in osteoarthritis-modulation of oxidative stress
KR102151155B1 (ko) 난청의 예방 또는 치료용 조성물
RU2177307C1 (ru) Лечебно-косметическое средство
BRPI0417797A (pt) soro sangüìneo biologicamente ativo, métodos para produzi-lo e seus usos
CN103610676B (zh) 4-((吡啶-3-羧基)-氨基)-丁酸或其盐在制备治疗男性性功能勃起障碍疾病药物中的应用
Bivalacqua et al. EFFECT OF BONE MARROW TRANSPLANTED SICKLE HEMOGLOBIN AND HEMOLYSIS ON THE DEVELOPMENT OF PRIAPISM IN A NEW ANIMAL MODEL OF SICKLE CELL ANEMIAASSOCIATED PRIAPISM: 834

Legal Events

Date Code Title Description
FZDE Discontinued